Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci.
van den Berg, L
Bexe Lindskog, E
MetadataShow full item record
Genome-wide association studies have been successful in elucidating the genetic basis of colorectal cancer (CRC), but there remains unexplained variability in genetic risk. To identify new risk variants and to confirm reported associations, we conducted a genome-wide association study in 1,701 CRC cases and 14,082 cancer-free controls from the Finnish population. A total of 9,068,015 genetic variants were imputed and tested, and 30 promising variants were studied in additional 11,647 cases and 12,356 controls of European ancestry. The previously reported association between the single-nucleotide polymorphism (SNP) rs992157 (2q35) and CRC was independently replicated (p = 2.08 × 10-4 ; OR, 1.14; 95% CI, 1.06-1.23), and it was genome-wide significant in combined analysis (p = 1.50 × 10-9 ; OR, 1.12; 95% CI, 1.08-1.16). Variants at 2q35, 6p21.2, 8q23.3, 8q24.21, 10q22.3, 10q24.2, 11q13.4, 11q23.1, 14q22.2, 15q13.3, 18q21.1, 20p12.3 and 20q13.33 were associated with CRC in the Finnish population (false discovery rate < 0.1), but new risk loci were not found. These results replicate the effects of multiple loci on the risk of CRC and identify shared risk alleles between the Finnish population isolate and outbred populations.
Version of record
genetic predisposition to disease
genome-wide association study
Genetic Predisposition to Disease
Genome-Wide Association Study
Polymorphism, Single Nucleotide
Molecular & Population Genetics
License start date
Int J Cancer, 2018, 142 (3), pp. 540 - 546
Showing items related by title, author, creator and subject.
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. Saunders, EJ; Dadaev, T; Leongamornlert, DA; Al Olama, AA; Benlloch, S; Giles, GG; Wiklund, F; Gronberg, H; Haiman, CA; Schleutker, J; Nordestgaard, BG; Travis, RC; Neal, D; Pasayan, N; Khaw, KT; Stanford, JL; Blot, WJ; Thibodeau, SN; Maier, C; Kibel, AS; Cybulski, C; Cannon-Albright, L; Brenner, H; Park, JY; Kaneva, R; Batra, J; Teixeira, MR; Pandha, H; Govindasami, K; Muir, K; Easton, DF; Eeles, RA; Kote-Jarai, Z (2016-04)Germline mutations within DNA-repair genes are implicated in susceptibility to multiple forms of cancer. For prostate cancer (PrCa), rare mutations in BRCA2 and BRCA1 give rise to moderately elevated risk, whereas two of ...
Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer. Hafeez, S; Warren-Oseni, K; McNair, HA; Hansen, VN; Jones, K; Tan, M; Khan, A; Harris, V; McDonald, F; Lalondrelle, S; Mohammed, K; Thomas, K; Thompson, A; Kumar, P; Dearnaley, D; Horwich, A; Huddart, R (2016-04)Image guided adaptive radiation therapy offers individualized solutions to improve target coverage and reduce normal tissue irradiation, allowing the opportunity to increase the radiation tumor dose and spare normal bladder ...
Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer. Reis Ferreira, M; Khan, A; Thomas, K; Truelove, L; McNair, H; Gao, A; Parker, CC; Huddart, R; Bidmead, M; Eeles, R; Khoo, V; van As, NJ; Hansen, VN; Dearnaley, DP (2017-12-01)PURPOSE: To investigate the feasibility of dose escalation and hypofractionation of pelvic lymph node intensity modulated radiation therapy (PLN-IMRT) in prostate cancer (PCa). METHODS AND MATERIALS: In a phase 1/2 study, ...